We evaluated the effects of nitric oxide (NO) generators and endogenous production of NO elicited by substance P (SP) in the angiogenesis process. Angiogenesis was monitored in the rabbit cornea in vivo and in vitro by measuring the growth and migration of endothelial cells isolated from coronary postcapillary venules. The angiogenesis promoted in the rabbit cornea by [Sar9]-SP-sulfone, a stable and selective agonist for the tachykinin NK1 receptor, and by prostaglandin E1 (PGE1), was potentiated by sodium nitroprusside (SNP). Conversely, the NO synthase inhibitor N omega-nitro-L-arginine methyl ester (L-NAME), given systemically, inhibited angiogenesis elicited by [Sar9]-SP-sulfone and by PGE1. Endothelial cells exposed to SNP exhibited an increase in thymidine incorporation and in total cell number. Exposure of the cells to NO generating drugs, such as SNP, isosorbide dinitrate, and glyceryl trinitrate, produced a dose-dependent increase in endothelial cell migration. Capillary endothelial cell proliferation and migration produced by SP were abolished by pretreatment with the NO synthase inhibitors N omega-mono-methyl-Larginine (L-NMMA), N omega-nitro-L-arginine (L-NNA), and L-NAME. Exposure of the cells to SP activated the calcium-dependent NO synthase. Angiogenesis and endothelial cell growth and migration induced by basic fibroblast growth factor were not affected by NO synthase inhibitors. These data indicate that NO production induced by vasoactive agents, such as SP, functions as an autocrine regulator of the microvascular events necessary for […] 
Introduction
Angiogenesis is the process of new vessel generation which leads to neovascularization (1) . In the adult tissue, angiogenesis is of importance for various physiological and pathological processes such as ovulation and corpus luteum formation, healing processes including recovery from myocardial infarction, tumor growth and metastasis, chronic arthropathies, and diabetic retinopathies.
The morphogenesis of capillaries involves a concerted sequence of events usually described as mobilization of the endothelium in a controlled direction, cellular proliferation, canalization of a solid bud, and production of the periendothelial stroma (2) .
Although a large number of vasoactive-vasodilating agents are reported to possess angiogenic activity (3-6) the relevance of vasodilation to the angiogenesis process is largely unknown. Endothelium-dependent vasodilation has been clearly demonstrated to be caused by the endothelium-derived relaxing factor identified as nitric oxide (NO)' (7, 8) which acts at the cellular level by increasing cyclic guanosine monophosphate (GMP) (9) .
The tachykinin substance P (SP) is released when noxious stimuli activate the peripheral endings of primary sensory neurons, causing vasodilation and increased vascular permeability (10) . The vasorelaxant response to SP is endothelium dependent and is mediated by NK1 receptors (11, 12) . Recently we have shown that SP activates cyclic GMP production in the capillary endothelium (13) and that NO-generating drugs promote endothelial cell proliferation in vitro (14) . Furthermore, reports from our group and others have indicated that SP, via NK1 receptors, promotes angiogenesis in vivo, endothelial cell growth, and mobilization in vitro (15) (16) (17) . These observations have lead us to hypothesize that there is a link between NO production from capillary endothelium and angiogenesis. In the present study we have investigated the role played by NO in the angiogenesis process promoted by SP. Angiogenesis was studied in vivo using the rabbit cornea assay and in vitro on capillary endothelial cells.
Methods
Angiogenesis in vivo: rabbit cornea assay. The angiogenic activity was assayed in vivo using the rabbit cornea assay (18) . Angiogenesis was studied in the cornea of albino rabbits since this is an avascular and transparent tissue where inflammatory reactions and growing capillaries can be easily monitored and changes quantitated by stereomicroscopic examination (19) . Slow-release pellets (1 x 1 x 0.5 mm) were prepared in sterile conditions incorporating the test substances into a casting 1. Abbreviations used in this paper: Ach, acetylcholine; bFGF, basic fibroblast growth factor; CVEC, coronary venular endothelial cells; GMP, guanosine monophosphate; GTN, glyceryl trinitrate; ISDN, isosorbide dinitrate; L-NAME, Nw-nitro-L-arginine methyl ester; L-NMMA, Nw-mono-methyl-L-arginine; L-NNA, Nw-nitro-L-arginine; MeB, methylene blue; NA, noradrenaline; NO, nitric oxide; PGE,, prostaglandin El; SNP, sodium nitroprusside; SP, substance P.
solution of an ethynyl-vinyl copolymer (Elvax-40), in 10% methylene chloride (10 MI/droplet). In the lower half of New Zealand White rabbit eye (Charles River, Calco, Como, Italy), anesthetized by sodium pentothal (30 mg/kg), a micro pocket (1.5 X 3 mm) was surgically produced using a pliable iris spatula 1.5 mm wide. The pellets were implanted in the micropockets located in the transparent avascular corneal stroma. Subsequent daily observations of the implants were made with a slit lamp stereomicroscope without anesthesia. An angiogenic response was scored positive when budding of vessels from the limbal plexus occurred after 3-4 d and capillaries progressed to reach the implanted pellet according to the scheme previously reported (18) . Angiogenic activity was expressed as the number of implants exhibiting neovascularization over the total implants studied. Potency was scored by the number of newly formed vessels and by their growth rate. Data were expressed as angiogenesis score, calculated as vessel density x distance from limbus in mm. A density value of 1 corresponded to 0 to 25 vessels per cornea; 2, from 25 to 50; 3, from 50 to 75; 4, from 75 to 100; and 5, for more than 100 vessels.
Experimental designs. (a) To test the potentiation of the angiogenic response by NO generator, two adjacent pockets were surgically produced in the same cornea, one bearing the angiogenic trigger and the other sodium nitroprusside (SNP) or control. Prostaglandin E1 (PGE1) and a stable analogue of SP, [Sar]-SP-sulfone which selectively activates tachykinin NK1 receptors (20) , were tested at doses of 0.1 Ig and 0.5 pg/pellet, respectively, which produced a weak angiogenic response as previously reported (3, 15 of five rabbits receiving L-NAME treatment for 10 d was returned to normal diet for 2 wk and then tested for angiogenesis. Platelet aggregation and cyclic nucleotide levels. Blood samples from control, D-NAME, and L-NAME-treated rabbits were taken 10 and 18 d after beginning of the treatment. In three animals blood samples were also taken 21 d after discontinuation of the treatment. Washed rabbit platelets were prepared as described by Radomski and Moncada (22), with minor modifications. Indomethacin (10 MM) was added to the final platelet suspension to prevent the formation of cyclooxygenase products. The platelet count was adjusted to 1.5-2 X 108/ml. A suspension of washed platelets was incubated at 370C for 4 min in a Payton dual channel aggregometer with continuous stirring at 1,000 rpm and then stimulated with thrombin (40-60 mU/ml) to give a submaximal aggregation (80-90%). The decrease in optical density was recorded for 5 min and data were expressed as percent of platelet aggregation obtained with platelets of control animals. To measure cyclic GMP levels, 500 jl of 5% TCA were added to the samples of stirred and nonstirred platelets. TCA from the supernatant was extracted with 0.5 M tri-n-octylamine dissolved in 1,1,2 trichloro-trifluoroethane. Levels of cyclic GMP in the aqueous phase were measured by radio-immunoassay in duplicate with prior acetylation of samples with acetic anhydride using iodinated tracer (13 
NNA) and L-NAME, and methylene blue (MeB) were used to inhibit NO synthase and guanylate cyclase (23), the drug used was added 1 h before the agonist.
Proliferation studies. For the proliferation studies, the same protocol as for [3H]thymidine incorporation was followed. At the end of each incubation time the supernatants were removed from the multi-well plates and cells were fixed by adding 1 ml of ice-cold methanol and kept at 4°C overnight. Cells were then stained with Diff-Quik. Cell numbers were obtained by counting by microscopic examination at l0x with the aid of an ocular grid (21 mm2). Each well was divided in 10 fields and cells were counted by double blind procedure in seven randomly selected fields. The total cell number/well was calculated by the formula: m x R x I, where m is the mean cell number/field, R is the ratio between the area of the well and the area of the ocular grid, and I is the magnification used. Values are expressed as total cell number/ well.
Migration assay. The Boyden Chamber procedure was used to evaluate cell migration (17) . The method is based on the passage of endothelial cells across porous filters against a concentration gradient of the migration effector. The Neuro Probe 48-well micro-chemotaxis chamber (Nuclepore Corp., Pleasanton, CA) was used. The two wells were separated by a polyvinyl-pyrrolidone (PVP)-free polycarbonate filter, 8 Jim pore size, coated with type I collagen and fibronectin. Test solutions were dissolved in DME + 1% FCS and placed in the lower wells. 50
Ml of cell suspension (2.5 x 104 cells) was added to each upper well.
In the experiments with NO synthase inhibitors, cell suspension was incubated with the inhibitors at 37°C for 30 min before the seeding. Determination of NO synthase activity. CVEC were seeded in 100-mm culture dishes and allowed to grow to 90% confluence. Cells were treated for 24 h with test substances in DME plus 1% FCS. At the end of incubation, cells were washed and scraped in Dulbecco's PBS. Samples were kept at -20'C until use. Cells were homogenized in buffer containing 0.32 M sucrose, 20 mM Hepes buffer, 1 mM EDTA, and 1 mM DTT and centrifuged at 39,000 g for 30 min. The NO synthase activity was then assayed using 340 td of the supernatant, which was incubated with 60 j1 of an incubation medium of the following composition: 2 mM NADPH+, 0.45 mM CaCI2, 10 HtM calmodulin, 200 mM arginine, 3H-L-arginine (5 ,uCi/ml) in a total volume of 400 p1. After 60 min of incubation at 37°C the mixture was loaded on 1 ml Dowex AG5OWX-8 (Na+ form) column and eluted by 5 ml of bidistilled water.
[3H]Citrulline obtained by this procedure was measured by a / counter and the ratio between labeled citrulline (dpm) and mg protein assayed in the homogenate was taken as NO synthase activity (24) . To verify whether Ca2' concentration could affect changes of NO synthase activity, CVEC homogenates were also resuspended in Ca2+ free buffer containing 1 mM EGTA. Furthermore, the calmodulin inhibitor trifluoperazine (100 uM) was used to evaluate the calmodulin-independent NO synthase.
Statistical analysis. The data are reported as means±SEM of experiments. Statistical analysis was performed by using one-way analysis of variance followed by Sheffe's test and by Student's t test for paired and/or unpaired data. A P value < 0.05 was taken as significant.
Materials. All reagents for cell culture were from GIBCO, UK. (Fig. 1 A) . When SNP (1 Mg) was released into the corneal stroma simultaneously with PGE1 or [Sar9]-SP-sulfone, a sharp improvement in the efficiency of the angiogenesis response was observed (Fig. 1  B) . The number of implants exhibiting positive angiogenesis was 5 out of 6 and 6 out of 6 for [Sar9]-SP-sulfone and for PGE1, respectively. The intensity of the angiogenic response, quantified by the number of new vessels and their growth rate, was potentiated during each observation (Fig. 2, A and B) . SNP alone (1 ,g/pellet) elicited in 30% of the implants the budding Effect of systemic L-NAME treatment on angiogenesis in vivo. The relevance of endogenous NO production to the angiogenesis process was tested by systemic administration of the NO synthase inhibitor L-NAME (21) . The angiogenic response after corneal implants of PGE1 0.25 pg/pellet and [Sar9]-SPsulfone 1 Iug/pellet is reported in Fig. 1 C. When rabbits were fed in the drinking water with L-NAME (0.5 g/l) for 1 wk before surgery, angiogenesis was drastically reduced (Table I , Fig. 1 D) . Conversely, treatment with the inactive enantiomer D-NAME or with a lower concentration of L-NAME (0.1 g/l) did not modify the angiogenic response to either stimuli. When animals receiving chronic L-NAME treatment were returned to normal diet, the corneal implants of PGEI and [Sar9]-SP-sulfone produced angiogenesis as in control untreated rabbits (3 positive implants out of 3 and 2 positive implants out of 3, respectively). The angiogenic response induced by bFGF (0.1 g/pellet) and measured at day 10 after pellet implantation, was not abolished by systemic treatment with L-NAME (0.5 g/l). (Fig. 3 A) . As a positive control for cell growth, the cells were challenged with the recombinant peptide growth factor bFGF (10 ng/ml) at each time point. The extent of SNP-induced DNA synthesis was similar to that obtained with bFGF.
The increase in thymidine incorporation promoted by SNP was paralleled by a concentration-dependent increment of the total cell number (Fig. 3 B) (21) . NO modify basal DNA synthesis. Thymidine incorporation produced by SP was reduced by L-NMMA, L-NAME, and L-NNA at all concentrations tested (Fig. 4) . To assess the specificity of NO synthase inhibition on the reduction of cell growth, cells were also challenged with D-NAME. CVEC treated with D-NAME did not modify their proliferative response to 10 nM SP as compared with the untreated control cells (41.5+6% and 34.5+8% increment over basal, respectively).
Further support for a role of NO production in mediating the proliferative response evoked by SP was also evidenced by the effect of MeB (1 tIM), an inhibitor of guanylate cyclase (21) , which abolished the increase of thymidine incorporation elicited by SP at all the concentrations tested (Fig. 5) . Effect of NO-donor drugs on endothelial cell migration. Endothelial cell mobilization at the microvascular level is a prerequisite for the neovascular response to occur in vivo (2) . NO generating drugs were tested for their ability to promote in vitro endothelial cell migration. Increasing concentrations of ISDN, GTN, and SNP were used. All drugs induced a concentration-dependent increase of CVEC migration (Fig. 6) . Effect of NO synthase inhibition on SP-induced migration. SP produces a concentration-dependent effect on endothelial cell migration (17) . Concentrations producing submaximal (1 nM) and maximal (10 nM) effects were used in these experiments (see Fig. 7 ). In cells pretreated for 30 before the exposure to SP, SP-effects were abolished. The effects produced by 10 nM bFGF were not (Fig. 8) . Inhibition of SP-induced migration by blockade of NO synthase was specific since D-NAME was ineffective (Fig. 9 A) , and the effect of L-NMMA was reverted by addition of L-arginine (200 ,M) (Fig.   9 B) . Effects of SP on NO synthase activity in CVEC. Subconfluent monolayers of CVEC were analyzed for NO synthase activity after 24 h exposure to 10 nM SP, a concentration known to produce maximal biological response in capillary endothelial cells (15, 17) . In resting conditions the activities of calciumdependent and calcium-independent isoforms of NO synthase were detected. In cells exposed to 10 nM SP the activities of both isoforms were increased compared with basal values (Fig.  10 ). In the presence of calcium, the NO synthase activity in CVEC stimulated with SP increased by 351%. When the cell homogenates were resuspended in Ca2+-free buffer (EGTA 1 mM) and in the presence of the calmodulin inhibitor trifluoperazine (100 ,M), the NO synthase activity increased slightly but (26, 27) , promote growth and mobilization of capillary endothelium in vitro in a dose-dependent fashion (14) . We also present evidence that the release of NO mediates endothelial cell proliferation and migration and angiogenesis induced by the vasoactive agent SP, but not by bFGF. The L-arginine NO pathway was activated in cells exposed to SP. Both isoforms of NO synthase, the calcium-dependent and the calcium-independent (28), are present in resting conditions in the endothelial cells used in this study. SP markedly increased the activity of the calcium-dependent isoform of the enzyme. Moreover, NO synthase inhibitors abolished the proliferation and migration of endothelial cells induced by SP, indicating that endogenous NO production is involved in the cellular effects promoted by this peptide. That NO is specifically involved in the signal transduction following tachykinin receptor activation is further indicated by the observations that the inactive enantiomer D-NAME was ineffective and L-arginine reverted the inhibition induced by L-NAME.
NO exerts its effect by activating a soluble guanylate cyclase (9) . In keeping with the hypothesis that NO synthase is stimulated by SP, we found that SP activates cyclic GMP production in CVEC (13) . This elevation was significantly reduced by the NO synthase inhibitor L-NMMA, thus indicating that NO production is directly involved (13) . A role for guanylate cyclase in mediating the proliferative effect of SP is further suggested by the observation that methylene blue selectively blocked the proliferation of CVEC induced by SP.
Inhibition of NO production caused by chronic systemic administration of L-NAME in vivo strongly curtailed the ability of SP and PGEI to elicit the neovascular response. NO-mediated processes (basal cyclic GMP levels in platelets and thrombininduced platelet aggregation, as well as Ach-induced dilation of aortic rings) were inhibited after addition of L-NAME in drinking water, indicating that this treatment provided an effective and long-lasting inhibition of NO production. The impairment of the angiogenic response after NO synthase inhibition is reversible since it was restored after discontinuation of the treatment. These data document that NO production is an essential step for angiogenesis induced by PGEI and SP.
Angiogenesis relies essentially on the ability of capillary endothelium to migrate and proliferate (2) . The extent of proliferation and migration obtained with the NO generating drugs is of the same magnitude as that produced by bFGF. However, NO production does not seem to be involved in the effect of bFGF at cellular level. In fact, inhibition of NO synthase both in vivo and in vitro failed to modify growth and migration of capillary endothelium promoted by bFGF, indicating that more than one pathway contributes to the cellular events leading to angiogenesis (29) (30) (31) ; the prevention of SP-or PGEI-induced angiogenesis by NO synthase inhibitors is consequent to selective blockade of one of these specific effector pathways.
Neovascularization is of relevance during inflammation, wound healing, and tumor growth and the study of these processes has resulted in the identification of a wide variety of angiogenesis inducers (3, 4, 15, 19) . The morphogenetic program of the neovascular response requires multiple steps, and an increase in blood flow and vasodilation of the parent venule before the emergence of the first capillary sprouts are important steps (6, 32) . SP During the completion of this report a paper appeared indicating a role for NO in monocyte-induced angiogenesis (34) .
In contrast, a previous report had indicated that inhibition of NO synthase in the chorioallantoic membrane of the chick embryo alters the development of microvessel (35) . The data obtained by Leibovich et al. (34) as well as our data were obtained Nitric Oxide Mediates Angiogenesis in adult and highly differentiated cells, a fact that might explain these differences.
Overall, the results obtained in this study provide the first evidence that endothelial NO has a physiological role in the modulation of angiogenesis triggered by vasoactive agents such as SP, acting through autocrine-paracrine mechanisms.
